What are the recommended dosing regimens, contraindications, and adverse effects of doxepin for treating depression and insomnia?

Doxepin for Insomnia and Depression

For insomnia, use low-dose doxepin (3-6 mg) specifically for sleep maintenance problems; for depression, use standard antidepressant doses (75-150 mg daily). These are fundamentally different clinical applications with distinct dosing regimens that should not be confused.

Dosing Regimens

For Chronic Insomnia (Sleep Maintenance)

Low-dose doxepin 3-6 mg at bedtime is recommended for sleep maintenance insomnia in patients unable or unwilling to receive cognitive behavioral therapy for insomnia (CBT-I) 1. The evidence shows:

• 3 mg dose: Improves total sleep time by 26-32 minutes and reduces wake after sleep onset by 22-23 minutes compared to placebo, with small-to-moderate improvement in sleep quality 2
• 6 mg dose: Improves total sleep time by similar amounts with moderate improvement in sleep quality 2
• Both doses significantly improve sleep efficiency (objective measures exceeding clinical significance thresholds) 2

Important context: CBT-I should be the initial treatment when possible, as it demonstrates superior long-term outcomes compared to all pharmacotherapy 1. Low-dose doxepin is positioned as a second-line option when behavioral interventions are not feasible.

For Depression

For depression, start with 75 mg daily, with usual optimal range of 75-150 mg/day 3. More severely ill patients may require gradual increases up to 300 mg/day, though additional benefit beyond 300 mg/day is rare 3. The total daily dose can be given as divided doses or once daily at bedtime (maximum 150 mg for once-daily dosing) 3.

Critical distinction: The low doses used for insomnia (3-6 mg) do NOT constitute adequate treatment for major depression 4. Anti-anxiety effects appear before antidepressant effects, with optimal antidepressant response taking 2-3 weeks 3.

Mechanism and Clinical Application

At low doses (3-6 mg), doxepin selectively antagonizes histamine H1 receptors with subnanomolar affinity, promoting sleep initiation and maintenance without significantly affecting other receptor systems 5, 6. This selective mechanism distinguishes it from higher antidepressant doses that engage multiple neurotransmitter systems.

Treatment sequencing for insomnia 4:

1. First-line: Short-intermediate acting benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon, temazepam) or ramelteon
2. Second-line: Alternate BzRA or ramelteon if initial agent unsuccessful
3. Third-line: Sedating antidepressants including low-dose doxepin (especially with comorbid depression/anxiety)

Contraindications and Precautions

Absolute contraindications:

• Concurrent MAO inhibitor use or within 14 days of discontinuation 3
• Glaucoma (risk of angle closure) 3

Use with extreme caution in:

• Compromised respiratory function (asthma, COPD, sleep apnea) 4, 3
• Hepatic or cardiac dysfunction 4, 3
• Elderly patients (start at lowest doses: 1 mg for low-dose insomnia formulation, 25-50 mg for depression) 3
• Pregnancy and nursing (not recommended) 4

Important drug interactions:

• Cimetidine: Can cause clinically significant elevations in tricyclic levels with severe anticholinergic symptoms (dry mouth, urinary retention, blurred vision) 3
• Alcohol: Potentiates effects and increases overdose danger 3
• Tolazamide: Case report of severe hypoglycemia in diabetic patient 3

Adverse Effects

Low-Dose Doxepin (3-6 mg for Insomnia)

The adverse event profile is remarkably benign at low doses. Meta-analyses show no statistically significant differences from placebo in overall adverse events 1, 2. Specific findings:

• Mild increase in somnolence at 6 mg dose 2
• No evidence of rebound insomnia upon discontinuation 2, 5
• No evidence of tolerance, psychomotor impairment, or withdrawal symptoms in trials up to 12 weeks 5, 6
• No consistent next-day impairment 2

However, the suicide risk associated with low-dose doxepin as a hypnotic is unknown and cannot be excluded (no black box warning exists for low-dose formulation, but risk cannot be ruled out) 1.

Standard-Dose Doxepin (Depression Treatment)

Common adverse effects include 3:

Anticholinergic effects (most common):

• Dry mouth, blurred vision, constipation, urinary retention
• May require dosage reduction if severe

CNS effects:

• Drowsiness (most common, tends to diminish with continued therapy)
• Confusion, disorientation, hallucinations
• Seizures, extrapyramidal symptoms, tardive dyskinesia (rare)

Cardiovascular: Hypotension, hypertension, tachycardia

Hematologic (rare but serious): Agranulocytosis, leukopenia, thrombocytopenia, purpura

Other: Weight gain, sexual dysfunction, SIADH

Withdrawal symptoms: Abrupt discontinuation after prolonged use can cause withdrawal (not addiction); gradual tapering recommended 3

Critical Safety Considerations

Suicide Risk

Patients with depression should be closely supervised during early treatment, as suicide risk is inherent and may persist until significant improvement occurs 3. Prescribe the smallest feasible amount initially.

Elderly Patients

Sedating drugs cause confusion and oversedation in the elderly; start at low doses and observe closely 3. Elderly patients have greater frequency of decreased hepatic, renal, and cardiac function requiring cautious dose selection 3.

Overdose

Deaths can occur from tricyclic antidepressant overdose 3. Critical manifestations include cardiac dysrhythmias, severe hypotension, convulsions, and CNS depression including coma 3. QRS duration ≥0.10 seconds on ECG indicates severity 3. Immediate cardiac monitoring and gastric decontamination are essential.

Monitoring and Follow-Up

• Initial phase: Follow patients every few weeks to assess effectiveness, side effects, and need for ongoing medication 4
• Long-term use: Employ lowest effective maintenance dose and attempt tapering when conditions allow 4
• Patient education: Discuss treatment goals, safety concerns, potential side effects, drug interactions, and risk of dosage escalation 4

Common Pitfalls to Avoid

1. Do not use low-dose doxepin (3-6 mg) to treat depression - this is inadequate dosing 4
2. Do not combine with alcohol - significantly increases toxicity risk 3
3. Do not abruptly discontinue after prolonged use - taper gradually to avoid withdrawal 3
4. Do not use standard antidepressant doses for simple insomnia - exposes patients to unnecessary anticholinergic and other side effects
5. Do not assume efficacy data for low-dose insomnia formulation applies to off-label use of higher doses - these are distinct clinical entities 4